Market news

BILLERICA, Mass., September 25, 2026--Quanterix Corporation (NASDAQ: QTRX) today reported significant progress on the Content Innovation Engine it introduced at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting new updates at the European Society for Spatial Biology (ESSB) September 28-October 1, 2026. This progress underscores Quanterix's growing leadership in spatial biology content, delivering the assays researchers need to do more pivotal work. Built on th

BILLERICA, Mass., September 17, 2026--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the "Inducement Grants") were made to James Gute, the recently appointed Chief Commercial Officer of the Company, and two other employees in connection with the commencement of their employment. The Inducement Grant to Mr. Gute consisted of 260,315 restricted stock Units ("RSUs") representing 260,315 shares of Q

BILLERICA, Mass., September 14, 2026--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this new role, he will provide medical and clinical leadership across Quanterix, partnering closely with the company’s Diagnostics, Scientific, R&D, Regulatory, and Commercial teams, to advance Quanterix’s innovative technologies and applications.

Motley Fool Press Release.

Quanterix (NASDAQ:QTRX) CEO Everett Cunningham said the company is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences, while acknowledging continued pressure in academic, government and biopharma marke

Quanterix (QTRX) is back in focus after its 10 August second quarter report, which paired higher revenue with a wider net loss, a lower full year 2026 revenue outlook, and a new Chief Commercial Officer. See our latest analysis for Quanterix. Quanterix’s share price has been under pressure for some time, with the year to date share price return down 59.18% and the 1 year total shareholder return down 44.85%. The stock briefly rebounded with an 8.47% 1 day share price gain after the 10 August...

Quanterix's Q2 revenue grew 34% but missed consensus, gross margins deteriorated, and a $26.9M impairment raised even more concerns. See why QTRX stock is a Hold.

Quanterix reported 34% second-quarter revenue growth and lower adjusted cash usage, but weaker-than-expected commercial performance prompted a substantial guidance reduction and pushed expected cash-flow break-even into 2027. Key Investor TakeawaysQuanterix (NASDAQ:QTRX) reported Q2 2026 revenue of $32.

Quanterix (NASDAQ:QTRX) reported second-quarter 2026 revenue of $32.9 million and lowered its full-year outlook after management cited broad-based market softness and commercial execution challenges. The company said revenue came in about $3 million, or 9%, below the guidance it provided in May. Re

BILLERICA, Mass., August 04, 2026--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August 10, 2026, at 8:30 AM ET, to discuss its second quarter 2026 financial results.

Dublin, July 21, 2026 (GLOBE NEWSWIRE) -- The "Biomarker Collaboration and Licensing Deals 2016-2026" has been added to ResearchAndMarkets.com's offering.This report provides a comprehensive and structured analysis of 590+ biomarker collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.The definitive benchmark for biomarker dealmaking Biomarker partnering is driven by data, discovery, and precisi

BILLERICA, Mass., July 16, 2026--Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass., July 14, 2026--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment.

Quanterix is back in focus after analysts trimmed their fair value price target from US$5.33 to US$4.33, tightening the implied upside range for the stock. Research firms describe this as a recalibration tied to refreshed assumptions rather than a wholesale change in the core outlook on Quanterix. Read on to see what is driving the revised targets, how bullish and cautious voices differ, and what it could mean for investors following the evolving narrative from here. Analyst Price Targets...